Aardvark Therapeutics' (AARD) Outperform Rating Reaffirmed at Royal Bank of Canada

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at Royal Bank of Canada in a research note issued on Tuesday,Benzinga reports. They currently have a $21.00 price objective on the stock. Royal Bank of Canada's price target would suggest a potential upside of 157.35% from the stock's current price.

Several other research firms have also issued reports on AARD. Bank of America increased their price objective on Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Morgan Stanley started coverage on Aardvark Therapeutics in a research note on Monday, March 10th. They issued an "overweight" rating and a $29.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday, April 1st.

Aardvark Therapeutics Trading Down 6.1 %

Shares of NASDAQ AARD traded down $0.53 during mid-day trading on Tuesday, hitting $8.16. The company had a trading volume of 208,458 shares, compared to its average volume of 146,422. Aardvark Therapeutics has a 12 month low of $6.79 and a 12 month high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 16,542 shares of the business's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Nelson Sun bought 10,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the purchase, the chief financial officer now directly owns 99,484 shares in the company, valued at approximately $1,591,744. The trade was a 11.18 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.